Pfizer-BioNTech vaccine - THE RIDGEWOOD BLOG.

the staff of the Ridgewood blog

Ridgewood NJ, the U.S. Food and Drug Administration took action approving and authorizing for emergency use updated COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death. Today’s actions relate to updated mRNA vaccines for 2023-2024 manufactured by ModernaTX Inc. and Pfizer Inc. Consistent with the totality of the evidence and input from the FDA’s expert advisors, these vaccines have been updated to include a monovalent (single) component that corresponds to the Omicron variant XBB.1.5.

Continue reading FDA Approves Updated mRNA COVID-19 Vaccines for Currently Circulating Variants

the staff of the Ridgewood blog

Ridgewood NJ, France and Germany joined Finland, Norway, and Sweden in recommending that the Moderna SARS-CoV-2 vaccine not be used for individuals under the age of 30 due to increased risk of myocarditis in that age group. Denmark has similarly recommended against offering the vaccine to individuals under the age of 18. French authorities recently emphasized, however, that vaccine effectiveness was slightly higher for the Moderna vaccine than for the Pfizer-BioNTech vaccine, and the Moderna product should be preferentially utilized for individuals aged 30 years or older. The European Medicines Agency (EMA) has authorized the Moderna vaccine for use in individuals aged 12 years and older.